Print

Onconova Therapeutics Inc. Announces Presentation of Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer at American Association for Cancer Research 2013 Annual Meeting  
4/10/2013 6:44:44 AM

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research (AACR) Annual Meeting.
//-->